Anticoagulant treatment of pediatric cerebral venous thrombosis has not been evaluated in
randomized trials. We evaluated the safety and efficacy of rivaroxaban and standard …

BACKGROUND: Emerging data suggest that direct oral anticoagulants may be a suitable
choice for anticoagulation for cerebral venous thrombosis (CVT). However, conducting high …

Abstract Background New Oral Anticoagulants (NOACs) such as Rivaroxaban are
introduced as alternatives to conventional vitamin-K antagonists in the long-term treatment …

Cerebral venous thrombosis (CVT) affects approximately 15 people per million annually and
represents 0.5% of all stroke [1, 2]. Initiation of anticoagulation with heparin followed by …

Wasay et al. New Oral Anticoagulants in Cerebral Venous Thrombosis https://doi.
org/10.5853/jos. 2019.00150 222 http://j-stroke. org to the discretion of the treating …

Background The relative importance of previous diagnosis and hereditary prothrombotic risk
factors for cerebral venous thrombosis (CVT) in children in determining risk of a second …

Background Venous thromboembolism (VTE) is a relatively rare condition in childhood with
treatment mainly based on extrapolation from studies in adults. Therefore, clinical trials of …

Background Treatment of venous thromboembolism in children is based on data obtained in
adults with little direct documentation of its efficacy and safety in children. The aim of our …

Background: Cerebral venous thrombosis (CVT) is an uncommon neurological condition
usually treated with heparin followed by oral vitamin K antagonists (VKAs). In patients with …

Cerebral venous thrombosis (CVT) causes significant disability and mortality. Current
guidelines for CVT management support the initial use of unfractionated heparin or low …